NCT01913054

Brief Summary

Gastroscopy, as a conventional examination for gastrointestinal tract disease, plays a very important role especially in early diagnosis and differential diagnosis of esophageal and gastric carcinoma. However, conventional gastroscopy is associated with several adverse effects (including throat discomfort, breath-holding, nausea, vomiting, laryngeal spasm and increased heart rate) due to which some patients are intolerant to this examination or even refuse the procedure due to fear of these effects. Recently, painless gastroscopy has been applied increasingly widely in outpatients to meet the increasing needs for comfortable medical care. Painless gastroscopy is commonly performed under general anesthesia without establishing an artificial airway. This is associated with an even higher anesthetic risk than general anesthesia in the operating room due to more basic patient monitoring and life-supporting equipment, only one anesthetist to perform anesthesia, fatigue in anesthesia, the requirement for a high turnover rate, as well as limited understanding of a patient's condition. Therefore, the availability of sedatives and analgesics which can provide rapid onset, sufficient sedation and analgesia, a short recovery time and less adverse effects are the premise of performing painless gastroscopy. Currently, combined intravenous anesthesia with fentanyl and propofol, commonly used in the clinic, is still associated with a long duration of action, hypotension in some patients and prolonged recovery. Etomidate has been increasingly utilized for in-clinic diagnosis and treatment for procedures such as painless coloscopy and early induced abortion due to its rapid onset, rapid metabolism and minimal impact on the circulatory and respiratory systems. However, no study on combined intravenous anesthesia with fentanyl and etomidate for painless gastroscopy had previously been reported. The main purpose of this study is to explore the efficacy and safety of combined intravenous anesthesia with fentanyl and etomidate for painless gastroscopy compared with the combination of fentanyl and propofol in middle aged and elderly patients, and to provide reliable evidence for the implementation and promotion of comfortable medical care.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,450

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Aug 2013

Shorter than P25 for phase_4

Geographic Reach
1 country

6 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 25, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 31, 2013

Completed
1 day until next milestone

Study Start

First participant enrolled

August 1, 2013

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

December 16, 2013

Status Verified

July 1, 2013

Enrollment Period

4 months

First QC Date

July 25, 2013

Last Update Submit

December 13, 2013

Conditions

Keywords

EtomidatePropofolPainless gastroscopy

Outcome Measures

Primary Outcomes (1)

  • Blood pressure

    Changes of blood pressure in each group will be recorded.

    baseline to 10 min after the operation, an expected average of 20 minutes

Secondary Outcomes (3)

  • Heart rate

    baseline to the end of the operation, an expected average of 30 minutes

  • Pulse Oxygen Saturation

    baseline to the end of the operation, an expected average of 10 minutes

  • Respiratory rate

    baseline to the end of the operation, an expected average of 10 minutes

Other Outcomes (6)

  • efficacy of anesthesia

    From the time when propofol is given to discharge, an expected average of 30 minutes

  • Satisfaction

    10 minutes after the operation

  • Recovery of anesthesia

    10 min, 15 min and 15 min after the operation

  • +3 more other outcomes

Study Arms (2)

Fentanyl & Propofol

ACTIVE COMPARATOR

0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.

Drug: Fentanyl InjectionDrug: Propofol Injection

fentanyl, propofol & etomidate

EXPERIMENTAL

0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.

Drug: Fentanyl InjectionDrug: Etomidate Fat Emulsion InjectionDrug: Propofol Injection

Interventions

Fentanyl & Propofolfentanyl, propofol & etomidate
Also known as: Fuerli
fentanyl, propofol & etomidate
Also known as: Jing'an
Fentanyl & Propofolfentanyl, propofol & etomidate

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Preparing to take gastroscopy;
  • Age:between 45 to 75 years old (middle-aged group: 45\~59 years old; elderly group: 60\~75 years old; the percentage of middle-aged group and elderly group are 60% and 40%, respectively);
  • BMI: between 18 to 25 kg/m2;
  • ASA classification: grade Ⅰ\~Ⅱ.

You may not qualify if:

  • Blood pressure before operation: \>180 mm Hg or \<90 mm Hg;
  • ECG before operation: \<50 beats per min;
  • HGB before operation: \<90 g/L;
  • Infected with respiratory inflammation and not cured within 2 weeks;
  • Sever heart, brain, pulmonary, heptic, renal diseases or diabetes;
  • History of difficult airway or abnormal recovery from anesthesia before or difficult airway is predicted to occur ;
  • Obvious electrolyte disturbance such as hyperkalemia;
  • Treated with immunosuppressants such as hormones for a long time or prior inhibition of the adrenal cortex;
  • Allergic to emulsion or opioids;
  • Concomitant other sedatives or analgesics (including injectable or oral administration of treatment related to Chinese Traditional Patent Medicines);
  • Suspected abuse of narcotic analgesics or sedatives;
  • Patients for whom it is difficult to cooperate or communicate because of abnormalities of neuromuscular system or mental disorder.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Chaoyang Hospital Attached to the Capital Medical University

Beijing, Beijing Municipality, 100020, China

NOT YET RECRUITING

General Hospital of Chinese Air Force

Beijing, Beijing Municipality, 100036, China

NOT YET RECRUITING

General Hospital of Chinese People's Liberation Army

Beijing, Beijing Municipality, 100853, China

COMPLETED

The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150086, China

RECRUITING

Renmin Hospital of Wuhan University Hubei General Hospital

Wuhan, Hubei, China

RECRUITING

The Affiliated Hospital of Xuzhou Medical College

Xuzhou, Jiangsu, 221006, China

NOT YET RECRUITING

MeSH Terms

Interventions

FentanylPropofol

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Weidong Mi, Senior

    General Hospital of Chinese People's Liberation Army

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Weidong Mi, Senior

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2013

First Posted

July 31, 2013

Study Start

August 1, 2013

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

December 16, 2013

Record last verified: 2013-07

Locations